В целом считается, что люди, страдающие астмой (ЛСА), подвергаются повышенному риску при респираторных
инфекциях, что ежегодно подтверждается во время в
...
пышек гриппа. Уже в начале пандемии COVID-19 широкое
распространение получило мнение о том, что ЛСА подвергаются более высокому риску в связи с COVID-19. Однако, по
мере накопления данных за 2020 г., связь между астмой и COVID-19 стала менее очевидной .
more
People with asthma (PWA) generally are considered at higher risk from respiratory infections, as is seen annually with influenza. At the outset of the COVID-19 pandemic, PWA were widely assumed to be at increased risk from COVID-19. However, as data emerged throughout 2020, the association between a
...
sthma and COVID-19 appeared less clear.
more
Die WHO hat mit Hilfe der Delphi-Methode eine klinische Falldefinition für das Post-COVID-19-Syndrom entwickelt, die 12 Domänen umfasst und in allen Bereichen verwendet werden kann. Diese erste Version wurde von Patienten, Forschern und anderen Personen aus allen WHO-Regionen entwickelt, wobei dav
...
on ausgegangen wird, dass sich die Definition ändern kann, wenn sich neue Erkenntnisse ergeben und sich unser Verständnis der Folgen von COVID-19 weiterentwickelt.
Die Post-COVID-19-Erkrankung tritt bei Personen mit einer wahrscheinlichen oder bestätigten SARS-CoV-2-Infektion in der Anamnese auf, in der Regel drei Monate nach dem Auftreten von COVID-19 mit Symptomen, die mindestens zwei Monate anhalten und nicht durch eine andere Diagnose erklärt werden können. Zu den häufigen Symptomen gehören Müdigkeit, Kurzatmigkeit, kognitive Störungen, aber auch andere Symptome, die sich im Allgemeinen auf das tägliche Leben auswirken. Die Symptome können nach der anfänglichen Genesung von einer akuten COVID-19-Episode neu auftreten oder nach der ersten Erkrankung fortbestehen. Die Symptome können auch schwanken oder im Laufe der Zeit wieder auftreten.
more
orientaciones provisionales, 23 de abril de 2020
Scientific Brief 9 July 2020
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv
...
e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
The purpose of this document is to provide guidance on the cleaning and disinfection of environmental surfaces in the context of COVID-19. This guidance is intended for health care professionals, public health professionals and health authorities that are developing and implementing policies and sta
...
ndard operating procedures (SOP) on the cleaning and disinfection of environmental surfaces in the context of COVID-19.
more
Updated 20 Nov. 2020
Countries can use this checklist of hospital governance, structures, plans and protocols to rapidly determine the current capacities of hospitals to respond to the COVID-19 pandemic and to identify gaps and major areas that require investment and action for the development of h
...
ospital readiness improvement plans. The tool can be used periodically to monitor hospital emergency operational readiness capacity development
more
N95 or equivalent respirators are single-use personal protective equipment (PPE) designed for use by health workers that provide direct care to patients with diseases transmitted by aerosols or during aerosol generating procedures (AGP) for patients with acute respiratory disease, as is the case of
...
COVID-19. • Given the current shortage of N95 and equivalent respirators, the World Health Organization (WHO) has suggested the possibility of their extended use by the same individual for up to 6 hours or the reprocessing of respirators when necessary.
more
The publication is designed to provide Ipas staff, trainers, partners and other health-care providers with access to up-to-date, evidence-based recommendations. In general, the recommendations are the same as those in the World Health Organization’s 2012 Safe Abortion: Technical and Policy Guidanc
...
e for Health Systems, Second edition. In rare cases, the recommendations have been modified due to the settings where Ipas works. In addition, if there is more current evidence to inform the recommendations, they will be updated here.
more
Purpose of review: We review recent evidence regarding risk factors for childhood posttraumatic stress disorder (PTSD) and treatment outcome studies from 2010 to 2012 including dissemination studies, early intervention studies and studies involving preschool children.
Miscellaneous
Chapter J.4
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv
...
e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program.
Guiding framework for development cooperation, Working paper 2017.
This document was drawn up on the basis of expert publications and inputs from partners in the
GIZ regional programme Psychosocial Support for Syrian and Iraqi Refugees and Internally
Displaced People1 in order to serve as guidanc
...
e in the design, implementation and assessment of
psychosocial support measures for refugees in the context of the crises in Syria and Iraq. It is
aimed at actors from the MHPSS sector working with refugees in the Middle East and at ministries
and academic/scientific institutions in the context of the Syria and Iraq crises.
more
Enfrentando la enfermedad de Alzheimer en los países en desarrollo.
Rev Neuropsiquiatr 80 (2), 2017 (P. 105-110)
Recibido: 03/02/2017 Aceptado: 12/06/2017
Miscelanea
Capítulo J.4
Editores: Matías Irarrázaval, Andres Martin, Laura Revert Martín & Sergio Jesús Soler Traductores: Sergio Jesús Soler, Nieves Hermosin Carpio, Clara De Castro & Beatriz Ortega